Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize tumor killing effect of an anti-VISTA monoclonal antibody in tumor bearing mice

被引：1
|
作者：
Jiang, Xiling
Leu, Jocelyn
Singh, Indrajeet
Snyder, Linda A.
Wang, Weirong
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2085
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Development of a mechanism-based pharmacokinetic/target occupancy/pharmacodynamic model to characterize the effect on neutrophil count by JNJ-61610588, an anti-VISTA monoclonal antibody, in cynomolgus monkeys
    Jiang, Xiling
    Niu, Jin
    Leu, Jocelyn
    Singh, Indrajeet
    Snyder, Linda A.
    Sun, Yu-Nien
    Wang, Weirong
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S120 - S121
  • [2] Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice
    Jiang, Xi-Ling
    Shen, Hong-Wu
    Mager, Donald E.
    Schmidt, Stephan
    Yu, Ai-Ming
    ACTA PHARMACEUTICA SINICA B, 2016, 6 (05) : 492 - 503
  • [3] Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice
    Xi-Ling Jiang
    Hong-Wu Shen
    Donald E.Mager
    Stephan Schmidt
    Ai-Ming Yu
    ActaPharmaceuticaSinicaB, 2016, 6 (05) : 492 - 503
  • [4] Anti-VISTA antibody enhances the anti-tumor immune response in mice with mammary tumors
    Jensen, S. M.
    Afentoulis, M.
    Wegmann, K. W.
    Campion, L.
    Snyder, L. A.
    Fox, B. A.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 109 - 109
  • [5] KVA12.1: AN ANTI-VISTA MONOCLONAL ANTIBODY WITH STRONG SINGLE AGENT ANTI-TUMOR ACTIVITY AND NO EVIDENCE OF CYTOKINE MEDIATED TOXICITY
    Guillaudeux, Thierry
    Lustig, Kurt
    Frazier, Emily
    Kabi, Neda
    Katz, Chen
    Peckham, David
    Xu, Mei
    Iadonato, Shawn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A446 - A446
  • [6] Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment
    Harrold, John M.
    Abraham, Anson K.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 (02) : 141 - 151
  • [7] Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment
    John M. Harrold
    Anson K. Abraham
    Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41 : 141 - 151
  • [8] Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients
    Chee M. Ng
    S. Bai
    C. H. Takimoto
    M. T. Tang
    A. W. Tolcher
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 207 - 217
  • [9] Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients
    Ng, Chee M.
    Bai, S.
    Takimoto, C. H.
    Tang, M. T.
    Tolcher, A. W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (02) : 207 - 217
  • [10] A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants
    Khan, David D.
    Lagerback, Pernilla
    Cao, Sha
    Lustig, Ulrika
    Nielsen, Elisabet I.
    Cars, Otto
    Hughes, Diarmaid
    Andersson, Dan I.
    Friberg, Lena E.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (11) : 3051 - 3060
12345